NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Forecast, Price & News $2.50 0.00 (0.00%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$2.47▼$2.5250-Day Range$2.48▼$3.1052-Week Range$1.85▼$3.14Volume453,317 shsAverage Volume579,062 shsMarket Capitalization$415.33 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arbutus Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside140.0% Upside$6.00 Price TargetShort InterestBearish2.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.44) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector898th out of 1,012 stocksPharmaceutical Preparations Industry447th out of 495 stocks 3.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Arbutus Biopharma has a forecasted upside of 140.0% from its current price of $2.50.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.58% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 1.4 News and Social Media Coverage News SentimentArbutus Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by InstitutionsOnly 31.03% of the stock of Arbutus Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.44) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arbutus Biopharma (NASDAQ:ABUS) StockArbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.Read More Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Stock News HeadlinesMay 17, 2023 | finance.yahoo.comHere's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn SituationMay 14, 2023 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Downgraded to Hold at StockNews.comMay 28, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 9, 2023 | finance.yahoo.comArbutus (ABUS) Upgraded to Buy: Here's WhyMay 9, 2023 | finance.yahoo.comArbutus to Present at JMP Securities Life Sciences ConferenceMay 6, 2023 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Upgraded to "Buy" by StockNews.comMay 5, 2023 | finance.yahoo.comQ1 2023 Arbutus Biopharma Corp Earnings CallMay 4, 2023 | markets.businessinsider.comArbutus Biopharma (ABUS) Gets a Buy from Chardan CapitalMay 28, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>May 4, 2023 | msn.comArbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn GuidanceMay 4, 2023 | msn.comRecap: Arbutus Biopharma Q1 EarningsMay 4, 2023 | finance.yahoo.comArbutus Reports First Quarter 2023 Financial Results and Corporate UpdateMay 3, 2023 | americanbankingnews.comArbutus Biopharma (ABUS) to Release Earnings on ThursdayMay 3, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUSApril 30, 2023 | americanbankingnews.comArbutus Biopharma Co. (NASDAQ:ABUS) Sees Significant Decline in Short InterestApril 27, 2023 | marketwatch.comBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arbutus Biopharma Corporation (ABUS) InvestigationApril 27, 2023 | finance.yahoo.comArbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023April 27, 2023 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Stock Rating Lowered by StockNews.comApril 26, 2023 | bizjournals.comArbutus Biopharma shares decline as FDA puts hold on drug study applicationApril 25, 2023 | finanznachrichten.deArbutus Biopharma Corporation: Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitorApril 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Arbutus Biopharma (ABUS)April 25, 2023 | finance.yahoo.comArbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitorApril 25, 2023 | finance.yahoo.comWhy Arbutus Biopharma Stock Is Sinking TodayApril 25, 2023 | finance.yahoo.comWhy Arbutus Biopharma Stock Is Plunging TodayApril 20, 2023 | finance.yahoo.comArbutus to Report First Quarter 2023 Financial Results and Provide Corporate UpdateApril 19, 2023 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by StockNews.comApril 18, 2023 | finance.yahoo.comArbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Company Calendar Last Earnings3/02/2023Today5/28/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees85Year Founded1992Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+140.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,460,000.00 Net Margins-211.41% Pretax Margin-211.41% Return on Equity-48.34% Return on Assets-34.74% Debt Debt-to-Equity Ratio0.02 Current Ratio6.08 Quick Ratio6.08 Sales & Book Value Annual Sales$39.02 million Price / Sales10.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book2.87Miscellaneous Outstanding Shares166,130,000Free Float157,163,000Market Cap$415.33 million OptionableOptionable Beta2.25 Social Links Key ExecutivesWilliam H. CollierPresident, Chief Executive Officer & DirectorMichael J. McElhaughChief Operating OfficerDavid C. HastingsChief Financial & Accounting OfficerMichael J. SofiaChief Scientific OfficerElizabeth HowardSecretary, Chief Compliance Officer & Executive VPKey CompetitorsEmergent BioSolutionsNYSE:EBSEntrada TherapeuticsNASDAQ:TRDAAerovate TherapeuticsNASDAQ:AVTEY-mAbs TherapeuticsNASDAQ:YMABErascaNASDAQ:ERASView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Bought 6,100 shares on 5/22/2023Ownership: 0.060%Arete Wealth Advisors LLCBought 15,000 shares on 5/22/2023Ownership: 0.009%JPMorgan Chase & Co.Bought 221,321 shares on 5/18/2023Ownership: 0.177%New York State Common Retirement FundSold 30,513 shares on 5/18/2023Ownership: 0.027%Jane Street Group LLCBought 4,242 shares on 5/16/2023Ownership: 0.082%View All Institutional Transactions ABUS Stock - Frequently Asked Questions Should I buy or sell Arbutus Biopharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABUS shares. View ABUS analyst ratings or view top-rated stocks. What is Arbutus Biopharma's stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month price targets for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 140.0% from the stock's current price. View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts. How have ABUS shares performed in 2023? Arbutus Biopharma's stock was trading at $2.33 at the start of the year. Since then, ABUS shares have increased by 7.3% and is now trading at $2.50. View the best growth stocks for 2023 here. Are investors shorting Arbutus Biopharma? Arbutus Biopharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,290,000 shares, an increase of 8.3% from the April 30th total of 3,960,000 shares. Based on an average trading volume of 903,200 shares, the days-to-cover ratio is currently 4.7 days. View Arbutus Biopharma's Short Interest. When is Arbutus Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ABUS earnings forecast. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Thursday, March, 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). The biopharmaceutical company had revenue of $6.25 million for the quarter, compared to analyst estimates of $6.31 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 48.34% and a negative net margin of 211.41%. What ETFs hold Arbutus Biopharma's stock? ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX). What is Arbutus Biopharma's stock symbol? Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS." Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.09%), Whitefort Capital Management LP (4.51%), Rubric Capital Management LP (2.53%), Hudson Bay Capital Management LP (1.65%), Geode Capital Management LLC (1.38%) and State Street Corp (1.24%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arbutus Biopharma's stock price today? One share of ABUS stock can currently be purchased for approximately $2.50. How much money does Arbutus Biopharma make? Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $415.33 million and generates $39.02 million in revenue each year. The biopharmaceutical company earns $-69,460,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. How can I contact Arbutus Biopharma? Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201. This page (NASDAQ:ABUS) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.